Evidence map›Paper›PMID 29088122›Full record

SynthesisInternational journal of molecular sciences2017

Xanthine Oxidase Inhibitors for Improving Renal Function in Chronic Kidney Disease Patients: An Updated Systematic Review and Meta-Analysis.

Anna Pisano, Valeria Cernaro, Guido Gembillo, Graziella D'Arrigo, Michele Buemi, Davide Bolignano

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 4 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 4 syntheses or guidelines pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial).Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2020
    Trial
  7. Trial
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Reactive Oxygen Species in Cystic Kidney Disease.Antioxidants (Basel, Switzerland) · 2024
    Review
  14. Review
  15. Metabolic profiling identifies the significance of caffeine metabolism in CKD.Frontiers in bioengineering and biotechnology · 2023
    Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Anna PisanoCNR-Institute of Clinical Physiology, 89124 Reggio Calabria, Italy. pisanoanna@hotmail.it.
Valeria CernaroChair of Nephrology, Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy. valecern82@virgilio.it.ORCID 0000-0003-4396-5032
Guido GembilloChair of Nephrology, Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy. guidogembillo@live.it.
Graziella D'ArrigoCNR-Institute of Clinical Physiology, 89124 Reggio Calabria, Italy. g.darrigostat@tin.it.
Michele BuemiChair of Nephrology, Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy. buemim@unime.it.
Davide BolignanoCNR-Institute of Clinical Physiology, 89124 Reggio Calabria, Italy. davide.bolignano@gmail.com.ORCID 0000-0003-3032-245X
Istituto di Fisiologia Clinica · ITUniversity of Messina · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAccruing evidence suggests that Xanthine Oxidase inhibitors (XOis) may bring direct renal benefits, besides those related to their hypo-uricemic effect. We hence aimed at performing a systematic review of randomized controlled trials (RCTs) to verify if treatment with XOis may improve renal outcomes in individuals with chronic kidney disease (CKD).

methodsOvid-MEDLINE, PubMed and CENTRAL databases were searched for RCTs comparing any XOi to standard therapy or placebo. The primary endpoint of interest was progression to End-Stage Kidney Disease (ESKD); secondary endpoints were changes in serum creatinine, glomerular filtration rate (eGFR), proteinuria and albuminuria.

resultsXOis treatment significantly reduced the risk of ESKD compared to the control (3 studies, 204 pts; RR = 0.42; 95% CI, 0.22, 0.80) and also improved eGFR in data pooled from RCTs with long follow-up times (>3 mo.) (4 studies, 357 pts; mean difference (MD) 6.82 mL/min/1.73 m²; 95% CI, 3.50, 10.15) and high methodological quality (blind design) (3 studies, 400 pts; MD 2.61 mL/min/1.73 m²; 95% CI, 0.23, 4.99). Conversely, no definite effects were apparently noticed on serum creatinine, proteinuria and albuminuria.

conclusionsXOis may represent a promising tool for retarding disease progression in CKD patients. Future trials are awaited to confirm the generalizability of these findings to the whole CKD population.

Indexed as

AgedAllopurinolEnzyme InhibitorsFebuxostatFemaleHumansMaleMiddle AgedNitrilesPyridinesRandomized Controlled Trials as TopicRenal Insufficiency, ChronicXanthine OxidaseAllopurinolEnzyme InhibitorsFebuxostatFYX-051NitrilesPyridinesXanthine Oxidaseallopurinolchronic kidney diseaseend-stage kidney diseasefebuxostattopiroxostatxanthine oxidase inhibitors

Identifiers

PMID29088122
PMCPMC5713253
OpenAlexW2767002831

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.